NLS Collaboration

Zelluna Immunotherapy has announced a research collaboration agreement with Lion TCR (Singapore). The collaboration will focus on the development of TCR-NK products for the treatment of virally induced cancers. “This collaboration represents a key milestone for Zelluna and marks an important aspect of our strategy which is to expand our pipeline through in-licensing and partnering,” […]

AstraZeneca’s BioVentureHub has established a new collaboration with medtech company Mölnlycke to support knowledge exchange across the Swedish life science industry. Small and medium-sized enterprises (SMEs) connected to AstraZeneca’s BioVentureHub will be offered free consultations with Mölnlycke experts with regard to developing products and solutions featuring medical device components. “With increasing focus on precision medicine, […]

Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO. The national research and innovation project Cancer IO started in May as a part of Business Finland’s Personalized Health Program. The project will develop new solutions to enhance immunotherapy treatments and support the introduction of new therapies. […]

The School of Health Innovation, founded by Karolinska Institutet, KI, Oslo University, UiO, and Norwegian University of Science and Technology NTNU, is the first Nordic initiative to offer courses in innovation as an extension of the academic subjects health sciences and life sciences. In addition, the University of Copenhagen will be joining the initiative shortly […]

AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause resistance […]

AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalized cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX’s personalized assay will be used in AstraZeneca’s recently launched Phase III MERMAID-1 trial to evaluate the effect of adjuvant treatment with […]